Gregory Korbel
Direttore operativo presso Atrin Pharmaceuticals, Inc.
Provenienza dei contatti di primo grado di Gregory Korbel
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 17 | |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Gregory Korbel tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Sales & Marketing | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Miscellaneous Commercial Services | Director of Finance/CFO Director of Finance/CFO | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Medical Specialties | Director/Board Member Director of Finance/CFO | |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Biotechnology | Director/Board Member | |
| The American University of Rome | College/University | Doctorate Degree | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Chairman Director/Board Member | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| SYNGENE INTERNATIONAL LIMITED | Miscellaneous Commercial Services | Director/Board Member | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Investment Managers | Private Equity Investor Private Equity Investor | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO | |
| NOVIMMUNE SA | Medical/Nursing Services | Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
| Tranzyme Pharma, Inc. (Canada) | Director/Board Member | ||
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
Anabasis SRL
 Anabasis SRL Miscellaneous Commercial ServicesCommercial Services Part of Dompé SpA, Anabasis SRL provides biopharmaceutical research and development services. The company is based in Milan, Italy. The Italian company was founded by Francesco Sinigaglia. Anabasis was acquired by Dompé SpA on February 27, 2012. | Miscellaneous Commercial Services | Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| SCPHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
| Cruz Blanca Initiative, Inc. | Founder | ||
| PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Founder Director/Board Member Director/Board Member | |
Carrick Therapeutics Ltd.
 Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Mosaic Biomedicals SL
 Mosaic Biomedicals SL Hospital/Nursing ManagementHealth Services Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain. | Hospital/Nursing Management | Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Consultant / Advisor | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| 5AM Partners V LLC | Corporate Officer/Principal | ||
| VOR BIOPHARMA INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| AKOUOS | Biotechnology | Director/Board Member | |
Rallybio LLC
 Rallybio LLC Miscellaneous Commercial ServicesCommercial Services Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Rallybio Holdings LLC
 Rallybio Holdings LLC Medical/Nursing ServicesHealth Services Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| ENTRADA THERAPEUTICS, INC. | Biotechnology | Chairman | |
| 5AM Opportunities I GP LLC | Corporate Officer/Principal | ||
Nucleome Therapeutics Ltd.
 Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| 501 ACQU | Financial Conglomerates | Chief Executive Officer | |
Immuneel Therapeutics Pvt Ltd.
 Immuneel Therapeutics Pvt Ltd. Hospital/Nursing ManagementHealth Services Immuneel Therapeutics Pvt Ltd. operates as a cancer treatment center. The company was founded by Kiran Mazumdar-Shaw, Kush M. Parmar and Siddhartha Mukherjee is headquartered in Bengaluru, India. | Hospital/Nursing Management | Founder | |
| 5am Partners Vi LLC | Corporate Officer/Principal | ||
| Nouscom Srl | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| RALLYBIO CORPORATION | Biotechnology | Director/Board Member Director/Board Member | |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Executive Officer Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 37 |
| Italia | 4 |
| Regno Unito | 4 |
| India | 3 |
| Svezia | 3 |
Settori
| Health Technology | 30 |
| Commercial Services | 6 |
| Finance | 5 |
| Health Services | 5 |
| Consumer Services | 4 |
Posizioni
| Director/Board Member | 146 |
| Corporate Officer/Principal | 59 |
| Independent Dir/Board Member | 47 |
| Chairman | 35 |
| President | 27 |
Contatti più connessi
| Insiders | |
|---|---|
| Kush Parmar | 32 |
| Scott Rocklage | 32 |
| Timothy Shannon | 28 |
| Guido Magni | 23 |
| Michael Kelly | 19 |
| Jonathan Hepple | 19 |
| Christian Schade | 18 |
| Richard Peters | 16 |
| Marc Duey | 15 |
| Gianni Gromo | 14 |
| John Hamill | 13 |
| John Henneman | 13 |
| Rifat Pamukcu | 12 |
| Michael Grissinger | 12 |
| Lars Abrahmsén | 11 |
- Borsa valori
- Insiders
- Gregory Korbel
- Connessioni Società
